- Home
- ALLO vs BIOA Comparison
ALLO vs BIOA Comparison
Compare ALLO & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLO | BIOA |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.4M | 681.9M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALLO | BIOA |
|---|---|---|
| Price | $2.17 | $17.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 6 |
| Target Price | $8.35 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 6.1M | 388.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $720.93 |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.99 | $3.93 |
| 52 Week High | $4.46 | $24.00 |
Technical Indicators
Market Signals| Indicator | ALLO | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 49.16 |
| Support Level | $2.12 | $15.49 |
| Resistance Level | $2.71 | $19.01 |
| Average True Range (ATR) | 0.14 | 1.17 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 57.27 | 51.56 |
Price Performance
Historical ComparisonAbout ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.